a no se i at foh put in wohd wetin yu fil we yu dokta tehl yu se yu geht bohst kansa. Na nɔmal tin fɔ gɛt bɔku kwɛstyɔn ɛn fred we de kam na yu maynd. Bɔt wan pan de impɔtant tin wae kin ɛp yu fɔ pas dis tranga waka na fɔ ɔndastand di rayt kayn kansa. Fɔ no di stej we di kansa de, di kayn we aw i de, in saiz, ɛn sɔm pan di prɔtin dɛn we de na yu kansa sɛl dɛn rili impɔtant fɔ disayd aw fɔ trit yu.
Fɔ tɔk am simpul wan, wetin na HER2-Negative?
Lɛ wi ɔndastand dis dis we. Di sɛl dɛn na wi bɔdi tan lɛk smɔl os dɛn. Dɛn os ya gɛt spɛshal ‘antena’ we kin gɛt mɛsej frɔm do. Insay mεdikal, wi kin kכl dεn rεsεpכta dεm ya. na frכm dεn antena dεm ya we wan sεl de gεt mεsej dεm lεk ‘fכ gro’ εn ‘fכ divayd’.
HER2 (Human Epidermal Growth Factor Receptor 2) na wan pan dɛn kayn spɛshal ɛntena dɛn de. HER2 de εp fכ kכntrכl di growth fכ di hεlty sεl dεm. כltu, sכmtεm di kεnsar sεl dεm de mek tu mכch pan dis HER2 εntena, bכku pas aw i nכmal. Dɔn di kansa kin gɛt mɛsej ɔltɛm we de tɛl am fɔ ‘grɔ’, ɛn di kansa kin bigin fɔ skata kwik kwik wan. Wi kin kɔl dis kɔndishɔn HER2-Positive .
So, if yu dɔktɔ se yu bɔdi kansa na HER2-negative , dat min se yu kansa sɛl dɛn nɔ gɛt dis ɛkstra HER2 ɛntena. Fɔ tɔk am simpul wan, yu kansa nɔ gɛt ɛni big tin we de mek i gro kwik kwik wan.
Dis na rili gud nyus to sɔm mak, bikɔs HER2-nɛgitiv kansa dɛn kin lɛk fɔ bi smɔl agresiv pas HER2-positiv kansa dɛn. di mכtalman in bכdi kεnsar dεm na di wכl dεn kכl dεm HER2-nεgεtiv.
Aw yu go no di HER2 stetɔs fɔ yu kansa?
di simptom dεm fכ כl tu di HER2-nεgεtiv εn HER2-positiv kεnsar dεm na di sem. Yu dɔktɔ nɔ go ebul fɔ tɛl yu us kayn yu gɛt jɔs bay we i de chɛk yu. I go nid fɔ tek smɔl sampul pan yu tumbu (bayɔpsi) ɛn mek dɛn tɛst am. dis tεst go no εksεkεkt כl di HER2 protin de insay di kεnsar sεl dεm.
Wi nid fɔ luk mɔ pas jɔs HER2!
Nɔto HER2 nɔmɔ de afɛkt di we aw kansa de gro. tu כda kayn rεsεpכta dεm ( hormone receptors - HR) de na wi bכdi we de sεnsitiv to כmon dεm.
- Ɛstrojen Risɛptɔ dɛn (ER) .
- Projesteron Risεptor dεm (PR) .
if dεn rεsεpכta dεm ya de pan di kεnsar sεl dεm, di כmon dεm we dεn kכl εstrojen εn projεstεron kin εp di kεnsar fכ gro. Dɔktɔ dɛn kin tɔk bɔt ɔl dɛn riseptɔ dɛn ya togɛda. Dis min se yu HER2-negativ kansa kin sheb to tu kayn:
1. HR-Positive / HER2-Negative: Dis min se di kansa nכ de sεnsitiv to HER2, bכt i de sεnsitiv to כmon dεm. Dis na di kayn kansa we kin kam pan pɔsin in bɔdi.
2. HR-Negative / HER2-Negative: Dis min se di kansa nכ de sεnsitiv to εni wan pan di HER2 כ כmon dεm. biכs כl tri pan dεn rεsεpכta dεm (HER2, ER, PR) nכ de, dεn kכl dis kayn tin bak Tripl Nεgεtiv .
If yu no ɔl dɛn tin ya, dat go ɛp yu ɛn yu dɔktɔ fɔ no klia wan bɔt di biyolojikal bihayvya fɔ yu kansa, we go ɛp yu fɔ pik di tritmɛnt we go fayn ɛn we go wok fɔ yu.
Wetin na di tritmɛnt dɛm fɔ HER2-negative kansa?
Bikɔs yu kansa na HER2-nɛgitiv, dɛn nɔ go gi yu targeted therapy, we de target di HER2 protin. dat na biכs di dכg dεm nid fכ gεt di HER2 εntena pan di kεnsar sεl dεm fכ wok. Bifo dat, dɛn go pik ɔda tritmɛnt dɛn bay di stej we yu kansa gɛt ɛn if i de sɛnsitiv to ɔmon.
- Ɔpreshɔn ɛn raytin: If dɛn no di kansa kwik kwik wan, ɔpreshɔn kin pul am kpatakpata. Dɛn kin tɛl yu bak fɔ yuz redyushɔn tɛrapi bifo ɔ afta di ɔpreshɔn.
- Endocrine/ Hormone therapy: Dis tritmɛnt rili impɔtant if yu kansa na HR-Positive/HER2-Negative. i de wok bay we i de ridyus di lεvεl dεm fכ di כmon dεm lεk εstrojen na di bכdi. We di ɔmon dɛn nɔ de igen, di kansa sɛl dɛn kin lɔs di mɛsej fɔ gro, ɛn di kansa kin smɔl ɔ i kin stɔp fɔ gro.
- Kimotɛrapi: Sɔntɛnde dɛn kin gi kimotɛrapi togɛda wit ɔmon tɛrapi fɔ HR-positiv / HER2-negative kansa. Dis kin dipen pan tin dɛm lɛk di stej ɛn gred fɔ di kansa, yu ej, ɛn yu ɔl wɛl bɔdi. Sɔntɛnde, di sayd ɛfɛkt dɛm we kemotɛrapi kin du kin pas di bɛnifit dɛm, so i impɔtant fɔ tɔk to yu dɔktɔ bɔt wetin bɛtɛ fɔ yu.
- Immunotherapy: If yu kansa triplɛ negatif ɛn advans, ɛn gɛt ɔda prɔtin we dɛn kɔl PD-L1, dis tritmɛnt kin bi opshɔn. I de wok bay we i de mek yu yon imyun sistɛm fɔ fɛt di kansa.
Aw fɔ si ɛn di tin dɛn we dɛn go tɔk bɔt
Di tin we impɔtant pas ɔl bɔt bɔdi kansa na fɔ fɛn am bifo i go na ɔda pat dɛn na di bɔdi. if yu HER2-nεgεtiv kεnsar de lokaliz to di brεst, di 5 ia rilitiv sכvayv rεt de rili hכy. Dis kin bi mɔ if yu kansa gɛt HR-positiv.
Tripul-negativ kansa na smɔl mɔ chalenj fɔ trit bikɔs dɛn nɔ de ansa to ɔmon tɛrapi ɔ HER2-targeted therapies. Dɛn kin fɛt bak mɔ.
Dis dɔŋ ya na di 5 ia rilitiv sɔvayv rɛt bay di stej we di kansa de. Dis na jɔs avrej, mɛmba se yu wan wan sityueshɔn kin difrɛn.
| Di kayn kansa we yu gɛt | Aw i dɔn skata | 5 ia rilitiv sɔvayv |
|---|---|---|
| HR-Pozitiv / HER2-Nɛgitiv (Di kayn we we kɔmɔn pas ɔl) | Limitɛd to di brɔst (Localized) . | 100% na di . |
| spred to di limf no dεm we de nia (rijכnal) . | 90% . | |
| Distant we de fa fawe | 31% . | |
| Tripul-Nɛgitiv (HR-Nεgεtiv / HER2-Nεgεtiv) | Limitɛd to di brɔst (Localized) . | 91% . |
| spred to di limf no dεm we de nia (rijכnal) . | 65% . | |
| Distant we de fa fawe | 12% . |
Nɔ mek yu fred fɔ dɛn nɔmba dɛn ya. Dis na jɔs avrej frɔm bɔku bɔku pipul dɛn. Di we aw yu wan wan de si tin go dipen pan bɔku tin dɛn, lɛk aw yu bɔdi de du tritmɛnt ɛn yu ɔl wɛl bɔdi. So, tɔk to yu dɔktɔ bɔt yu sik ɛn ɛni ɔda tɛst we yu go nid.
Mɛsej we dɛn kin kɛr go na os
- HER2-Negative min se yu kansa sel dεm nכ gεt wan ki protin we de mek dεn gro fast fast. Bɔrku tɛm dis kin mek dɛn kansa ya nɔr kin gɛt bɛtɛ trɛnk.
- Ivin if yu kansa na HER2-negative, fɔ no if i sɛnsitiv to ɔmon (HR-positiv) ɔ nɔ sɛnsitiv to (HR-negative) impɔtant fɔ no di tritmɛnt.
- Di tritmɛnt we dɛn kin pik kin dipen pan di kayn ɛn stej we di kansa gɛt, ɛn yu pasɔnal wɛlbɔdi. Ɔpreshɔn, redyushɔn tɛrapi, ɔmon tɛrapi, ɛn kemotɛrapi na di men tritmɛnt dɛn.
- Dis fɛt wit kansa nɔto sɔntin we yu fɔ du yu wan. Tɔk to yu dɔktɔ bɔt ɔl yu kwɛstyɔn ɛn tin dɛn we yu de fred. Fɔ gɛt di rayt infɔmeshɔn na yu big trɛnk pan dis waka.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt